Research and Markets - Biobanking Technologies - Expected to Reach $240.2 Billion in 2021 - Key Vendors are Novartis, Pfizer & Abbott Laboratories

DUBLIN, Dec 5, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Biobanking: Technologies and Global Markets" report to their offering.

The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.

This report entails forecasted and prevailing biobank products within the 2016 to 2021 period. Biobanks play a critical role in the development of new drugs. The document also features new FDA-approved products in 2015 and 2016, as well as those awaiting approval within the forecast period. The 2016 figures in this report are approximated except in cases where reports of exact results have been released; this is attributed to the timing of this report's release.

Emerging companies and the leading competitors in the prevailing global Biobanks industry are analyzed extensively in this report. The specific product strategies and products of leading drug manufacturers in the market are analyzed and profiled in the report. Biotechnology companies that utilize biobanks to develop new, novel products are also included in the analysis. New products expected to be introduced in the market within the forecast period and their manufacturers, in addition to their impact on the competitive biobank market are discussed in this report.

Companies Mentioned:

• Abbott Laboratories Inc.
• Affymetrix, Inc.
• Asterand Plc
• Astrazeneca Ltd
• Bayer Schering Pharma Ag
• Biochain-Genomics
• Biostorage Technologies, Inc.
• Boehringer Ingelheim Gmbh
• Bristol-Myers Squibb Co
• Daiichi Sankyo Company, Ltd
• Eli Lilly And Company
• Exiqon Life Sciences
• Glaxosmithkline
• Johnson & Johnson Ltd
• Millennium Pharmaceuticals
• Merck & Co.
• Novartis AG
• Pfizer Inc
• F. Hoffman-La Roche AG
• Sanofi-Aventis
• Scipac
• Takeda Pharmaceuticals Ltd
• Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

1: Introduction - Complimentary

2: Summary - Complimentary

3: Overview

4: Overview Of Biobank Applications

5: Current Biobanks Worldwide

6: Disease-Based Biobanks

7: Population Based Biobanks

8: For-Profit Biobank Companies

9: The Limitations Of Biobanks

10: Regulatory Dynamics, Intellectual Property, Ethical Considerations

11: Biobank Markets Forecast By Segment And Region

12: Detailed Description Of The Use Of Biomarkers

13: Company Analysis

For more information about this report visit http://www.researchandmarkets.com/research/2ssznz/biobanking

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---biobanking-technologies---expected-to-reach-2402-billion-in-2021---key-vendors-are-novartis-pfizer--abbott-laboratories-300372927.html

SOURCE Research and Markets